2026-01-15 - Analysis Report
## Merck & Co Inc Financial Report

### Company Overview
Pharmaceutical and healthcare company.

### Return Rate Comparison
- **Cumulative Return of Review Stock (Merck & Co Inc)**: 28.19%
- **Cumulative Return of Comparison Stock (S&P 500, VOO)**: 92.89%
- **Divergence**: -68.90, relative divergence: 23.20%
- **Difference in Cumulative Return**: 64.70%

### Alpha, Beta Analysis

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 24.0% | 14.7% | 21.0% | 0.7 | 182.1B |
| 2017-2019  | 37.0% | 14.7% | 20.0% | 0.7 | 216.8B |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7 | 195.0B |
| 2019-2021  | 0.0% | 19.3% | -43.0% | 0.6 | 191.4B |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5 | 277.1B |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3 | 272.3B |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3 | 248.5B |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3 | 262.9B |

### Recent Stock Price Fluctuations

- **5-day SMA**: $110.00
- **20-day SMA**: $106.08
- **60-day SMA**: $97.68
- **Current Close**: $111.01
- **Last-Market Price**: $111.01
- **Previous Close**: $108.26
- **Price Change**: $2.54

### RSI, PPO Index Indicators and Delta Prev Rel Divergence
- **Market Risk Indicator (MRI)**: 0.70
- **RSI**: 69.89
- **PPO**: -0.02
- **Hybrid Signal**: Buy
- **Risk Level**: Medium
- **Recent Relative Divergence Change**: -1.00 (-): worsening
- **7-day Rank Change**: -39 (-): rank down
- **7-day Dynamic Expected Return Change**: -3.30 (-): worsening
- **Expected Return**: -30.60%

### Recent News & Significant Events
- **FDA Fast-Tracks Two Merck (MRK) Drugs With Blockbuster Potential** - Yahoo Finance
- **Assessing Merck (MRK) Valuation After Mixed Short Term Returns And Modest Earnings Multiple** - simplywall.st
- **Is Merck Stockâ€™s Run Legitimate?** - Forbes
- **Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case** - Chartmill
- **Kera Capital Partners Inc. Buys 9,382 Shares of Merck & Co., Inc. $MRK** - MarketBeat
- **Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s** - Reuters

### Analyst Opinions

**Analyst Consensus:**
- **Key:** Buy
- **Mean:** 1.90 (~Buy)
- **Opinions:** 27
- **Target Price (avg/high/low):** $113.33 / $135.00 / $83.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|-----|----:|--------|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

### Financial Information

#### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | 17.28B | 77.69% |
| 2025-06-30 | 15.81B | 77.50% |
| 2025-03-31 | 15.53B | 77.98% |
| 2024-12-31 | 15.62B | 75.50% |
| 2024-09-30 | 16.66B | 75.51% |

#### Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | 51.85B | 11.16% |
| 2025-06-30 | 48.99B | 9.04% |
| 2025-03-31 | 48.34B | 10.51% |
| 2024-12-31 | 46.31B | 8.08% |
| 2024-09-30 | 44.50B | 7.09% |

### Comprehensive Analysis (Summary)

- The **cumulative return** of Merck & Co Inc is significantly lower than that of the S&P 500.
- The **Alpha, Beta analysis** indicates mixed performance across different periods.
- The **recent stock price fluctuations** suggest a sharp rebound in the short term.
- The **RSI, PPO index indicators** and **Delta Prev Rel Divergence** indicate a **medium risk level**.
- **Recent News & Significant Events** indicate potential growth opportunities for Merck & Co Inc.
- **Analyst opinions** recommend a **buy** rating with an average target price of $113.33.
- The **recent earnings analysis** shows mixed EPS and revenue growth.
- The **financial information** indicates strong revenue and profit margin growth.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.